UCB, Inc. v. Yeda Research & Development Co.

MEMORANDUM OPINION

LEONIE M. BRINKEMA, District Judge.

Plaintiff/Counterclaim-Defendant UCB, Inc. (“UCB”) brought this declaratory judgment action seeking a declaration that its Cimzia® product, a humanized monoclonal antibody approved by the Food and Drug Administration- (“FDA”) for the treatment of rheumatoid arthritis, psoriatic . arthritis, active ankylosing -spondylitis, and Crohn’s disease, does not infringe defendant’s patent and that the patent is invalid. Specifically, UCB argues that the defendant’s patent does not cover humanized .monoclonal antibodies like Cimzia®,…